ARTICLE | Company News
Nabi Biopharmaceuticals Inc., Braintree deal
June 30, 2003 7:00 AM UTC
NABI acquired from Braintree worldwide rights to PhosLo calcium acetate, which is marketed to control elevated phosphate levels (hyperphosphatemia) in patients with end-stage renal failure. NABI will...